Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
National Institutes of Health · National Institute of Allergy and Infectious Diseases · +2 more institutions
Abstract
Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging…
Citation impact
- FWCI
- 16.88
- Percentile
- 100%
- References
- 51
Authors
15- JDJulie DyallCorresponding
National Institutes of Health, National Institute of Allergy and Infectious Diseases
- CMChristopher M. Coleman
University of Maryland, Baltimore
- BJBrit J. Hart
National Institutes of Health, National Institute of Allergy and Infectious Diseases
- TVThiagarajan Venkataraman
University of Maryland, Baltimore
- MRMichael R. Holbrook
National Institutes of Health, National Institute of Allergy and Infectious Diseases
Topics & keywords
- Repurposing
- Drug repositioning
- Middle East respiratory syndrome coronavirus
- Medicine
- Drug development
- Middle East respiratory syndrome
- Drug
- Pharmacology
- Good health and well-being